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Paraoxonase-1 (PON1) has an anti-oxidative function in preventing the formation
of oxidized lipoproteins (LDL and HDL) and hydrolyzing the active metabolites of some
organophosphate insecticides (e.g., paraoxon and diazoxon) and other non-physiological
substrates. PON1Q192R affects PON1 hydrolytic activity and its protective role against
oxidative stress, thereby influencing susceptibility to cardiovascular disease among
individuals.
The objectives of this study were to determine the effect of race, gender, and age
on PON1 activities and PON1192 genotypes in Caucasian and African American
Southerners. Serum samples from 200 individuals (equally distributed race and gender
classes, ages 25-55) were assayed spectrophotometrically for paraoxon and diazoxon
hydrolysis.
Data indicate a positive correspondence between PON1192 genotypes and race
and PON1 activity and race. Data do not indicate an influence of gender and age on

PON1 activities or PON1192 genotypes. These results are useful in explaining the
increased risk of cardiovascular disease in African Americans compared to Caucasians.

Key words: PON1, polymorphism Q192R, cardiovascular disease, diazoxonase,
paraoxonase
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CHAPTER I
INTRODUCTION
Paraoxonase-1 (PON1) is an enzyme that has an anti-oxidative function in
preventing the formation of oxidized lipoproteins (LDL and HDL) and hydrolyzing the
active metabolites of some organophosphate insecticides (e.g., paraoxon and diazoxon)
and other non- physiological substrates (van Himbergen et al., 2006). PON1Q192R
polymorphism affects PON1 hydrolytic activity and its protective role against oxidative
stress, thereby influencing susceptibility to cardiovascular disease among individuals.
The R allele is less protective for cardiovascular disease due to its lesser capacity to
metabolize oxidized lipoproteins and its greater efficiency for hydrolyzing paraoxon
(Jarvik et al., 2002; Costa et al., 2005). The Q allele is more protective for cardiovascular
disease due to its efficient metabolism of oxidized lipoproteins and its greater efficiency
for hydrolyzing diazoxon than does the R allele. Recent studies have suggested that
diazoxon hydrolytic activity indicates the antioxidative ability of PON1 more than other
non-physiological substrates because of its association with HDL and LDL particle size,
and its dominance in the protective Q allele (Vekic et al., 2007).
Cardiovascular disease is more prevalent in the African American population than
the Caucasian population and causes higher annual age-adjusted mortality in the South
(except Florida) than in other regions of the country. The onset of CVD is caused by
environmental, dietary, and genetic influences. Knowledge of PON1192 enzymatic
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activities and genotypes as related to race, gender, and age within a population may
provide a useful explanation for a portion of the cardiovascular health disparity.
The measurement of PON1192 diazoxonase and paraoxonase activities in the
serum of African American and Caucasian Southerners may be used to indicate the
distribution of PON1192 genotypes (QQ, QR, and RR) and possible differences within
race, gender, and age associated with PON1192 activities. Data on the frequency
distribution of PON1192 genotypes have been reported on numerous populations, but not
specifically the Southern population. These data appear in journals such as:
Environmental Health Perspectives, European Journal of Clinical Investigation,
Experimental and Molecular Pathology, Human Biology, among others.
However, further studies are needed to understand the relationship between PON1
activities and genotypes and their role in cardiovascular disease, the distribution of PON1
phenotypes and genotypes within human populations, the possible differences of PON1
activities within race, gender, and age groups, and why PON1 activities are a better
predictor of cardiovascular disease than genotype. Also, studies of PON1 have not been
conducted on Southern populations or many African American populations, so neither the
activities of PON1 nor the proportion of the two genotypic forms (Q and R) of PON1 are
known among the individuals with the highest mortality rate from cardiovascular disease.
Our study samples came from Integrated Laboratory Services-Biotech (ILSbio),
which had obtained serum samples from blood banks in Alabama and Tennessee. The
Institutional Review Board approved the study protocol. A total of two hundred serum
samples were obtained from men and women, equally distributed race and gender classes,
who were self-identified as being Caucasian or of African American origin. The
2

following individuals were excluded from the study: subjects under the age of twentyfive or over sixty-five, subjects known or suspected to be infected with human
immunodeficiency virus or hepatitis, and subjects who were not Caucasian or AfricanAmerican. The cardiovascular health status, dietary and lifestyle habits, and
environmental toxicant exposure of subjects are unknown.
Our study will be the first to report the distribution of PON1192 genotypes in the
serum of African American and Caucasian Southerners and the possible differences in
PON1 (paraoxonase and diazoxonase) activities within race, gender, and age groups.
With the data obtained, we statistically determined that African Americans in the South
have lower DZOase/POase ratios than Caucasians and the frequency distribution of QQ,
QR, and RR genotypes differ between the two races. Data from our study strongly
suggest a positive correlation between mean DZOase/POase ratios and genotypes and
their role in increased susceptibility to cardiovascular disease in African Americans.
Also, these results can be used to compare with future studies in which more samples
may be obtained and/or more parameters are studied.
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CHAPTER II
LITERATURE REVIEW
Paraoxonase-1 (PON1) is a mammalian enzyme that is synthesized primarily in
the liver and is secreted into the blood, where it is associated with high- density
lipoproteins (Costa et al., 2004). The structure of PON1 is a six-bladed β- propeller with
two calcium ions (Ca1, Ca2) located in its central tunnel (Harel et al., 2004). The
catalytic calcium (Ca1) has higher solvent accessibility and the structural calcium (Ca2)
stabilizes the structure of PON1 (Harel et al., 2004; van Himbergen et al., 2006). PON1
belongs to a family of calcium-dependent hydrolases that also includes PON2 and PON3
(Gaidukov et al., 2006). The three classes hydrolyze aromatic and long-chain aliphatic
lactones, but PON2 and PON3 lack paraoxonase (phosphotriesterase) and arylesterase
activities (Costa et al., 2004).
PON1 hydrolyzes paraoxon (the active metabolite of the organophosphate
insecticide parathion), diazoxon (the active metabolite of the organophosphate insecticide
diazinon), chlorpyrifos- oxon (the active metabolite of the organophosphate insecticide
chlorpyrifos), organophosphate chemical warfare agents (e.g., soman and sarin), and
aromatic esters (e.g., phenyl acetate) as non-physiological substrates (van Himbergen et
al., 2006). Recent structure-activity model studies show that lactones are the preferred
substrate of PON1 and the physiological activity of PON1 is to act as an interfacially
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activated lipolactonase that associates with HDL carrying apolipoprotein A-I (apoA-I)
and apolipoprotein J (apoJ), with the prevention of atherosclerosis (Gaidukov et al.,
2006). PON1 has a physiological function for the prevention of the formation of
oxidized low-density lipoproteins (LDL), inactivation of LDL-derived phospholipids
once they are oxidized, and protection of phospholipids in high-density lipoproteins
(HDL) from oxidation (Costa et al., 2004).

Formation of Oxidized Lipoproteins (HDL and LDL)
Oxidized LDL originates from oxidation in the arterial wall by lipoxygenases and
myeloperoxidases. It has been proposed that biologically active lipids in LDL are formed
in three phases (Mertens and Holvoet, 2001; Navab et al., 2000). First, LDL interacts
with metabolic products of linoleic acid, metabolic products of arachidonic acid, and
hydrogen peroxides. Linoleic acid and arachidonic acid are polyunsaturated fatty acids
(PUFAs) that are protected from free radical attack and oxidation by several antioxidants.
PUFAs and antioxidant levels indicate LDL oxidation susceptibility (Ramos et al., 1995).
Second, LDL is trapped in the subendothelial space and continuous generation of
additional reactive oxygen species in LDL occurs. 15- Lipoxygenase converts
polyunsaturated fatty acids into lipid hydroperoxides causing oxidation of LDL; also 12hydroxyeicosatetraenoic acid is a lipoxygenase metabolite of arachidonic acid that can
cause greater adhesion of monocytes to endothelium (Mertens and Holvoet, 2001).
Third, the nonenzymatic oxidation of LDL phospholipids occurs, causing formation of
specific oxidized phospholipids that induce monocyte binding, chemotaxis, and
differentiation into macrophages (Mertens and Holvoet, 2001; Navab et al., 2000).
5

Myeloperoxidases generate reactive species that oxidize antioxidants, lipids, and protein
of LDL. Nitric oxide (reactive nitrogen species) can be converted to secondary oxidizing
species that increase membrane and lipoprotein lipid oxidation. Oxidized LDL leads to
atherosclerosis (Mertens and Holvoet, 2001).

Cardiovascular Disease
Approximately every year since 1900, cardiovascular disease (CVD) has been the
leading cause of death in the United States. In general, states in the South (except
Florida) have higher annual age- adjusted mortality rates from CVD and stroke than
states from other regions of the country (American Heart Association, Heart Disease, and
Stroke Statistics-2007 update). Some of the critical risk factors for CVD include:
hypertension, high cholesterol (particularly LDL cholesterol), smoking, and obesity. The
contributions of these risk factors to the state- specific age- adjusted mortality rates from
CVD are unknown. Several theories have been developed to explain the higher stroke
mortality rate (a subset of CVD mortality) in the South including: low socio-economic
status, an increased prevalence and severity of hypertension, and the presence of
environmental toxicants (Perry and Rocella, 1998). Soft water has been reported to be
associated with increased cardiovascular mortality because the southeastern region of the
United States has the largest soft water area in the U.S. (Perry and Rocella, 1998). The
CVD health disparity in the South suggests that an environmental factor(s) more
prominent in the South than in other regions of the country might synergize the known
risk factors, perhaps in conjunction with a genetic pre-disposition prominent in the South.

6

PON1 Protective Function
Earlier studies have suggested that the PON1 N-terminus anchors it to HDL,
thereby contributing to the antioxidative properties of HDL (Harel et al., 2004; Rozek et
al., 2004). In vivo studies in laboratory animals show that PON1 reduces the generation
of lipid peroxides by hydrolyzing biologically active LDL and preventing the formation
of fatty streak lesions (Gamboa et al., 2006; Watson et al., 1995). This function also
inactivates PON1 arylesterase activity by the interaction of oxidized LDL phospholipids
and cholesteryl esters with the PON1-free sulfhydryl group at cysteine-284 (Aviram et
al., 2000). PON1 has three cysteine (Cys) residues in positions 42, 284, and 353. Cys-42
and Cys-353 are essential for PON1 hydrolase activity while Cys-284 is close to the
active site and is essential for PON1 to be protective against LDL oxidation (Bartels et
al., 2002; Sorenson et al., 1995; Aviram et al., 1998; Costa et al., 2004). Paraoxonase
also causes HDL to become resistant to oxidation therefore maintaining the capacity of
HDL to participate in reverse cholesterol transport.
It has recently been shown that HDL particles carrying apolipoprotein A-I bind
PON1 with high affinity and greatly stabilize the enzyme and stimulate its lipolactonase
activity (Gaidukov et al., 2006). HDL and apolipoprotein A-I (apoA-I) inhibit the
oxidation of biologically active lipids. ApoAI-HDL causes LDL to become resistant to
oxidation by removing 13(S)-hydroxyperoxyoctadecadienoic acid [(13(S) - HPODE)]
and 15(S)-hydroxyperoxyeicosatetraenoic acid [(15(S) - HPETE)] from LDL. Both
enhance phospholipid auto- oxidation products such as 1-palmitoyl-2-arachidonoyl-snglycero-3-phosphocholine (PAPC) and 1-palmitoyl-2-glutaroyl-sn-glycero-3-
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phosphocholine (PGPC), as well as cholesterol linoleate (Mertens and Holvoet, 2001;
Navab et al., 2000).
Apolipoprotein J (apoJ) is a glycoprotein present in HDL with PON1 and apoA-I
that has been reported to function in complement regulation and prevention of cytolysis,
reverse cholesterol transport, apoptosis, and membrane protection at fluid-tissue
interfaces (Navab et al., 1997). Evidence has suggested that apoJ stimulates cholesterol
and phospholipid efflux from the human macrophage cell lines THP-1 and U937
therefore contributing to reverse cholesterol transport (Gelissen et al., 1998). Reverse
cholesterol transport involves removing excess cholesterol from peripheral cells and then
returning it to the liver for excretion as bile acids. Navab and colleagues (1997) reported
that pre- incubation of LDL or artery wall cells in co- culture with purified apoJ resulted
in a dose-dependent inhibition of LDL- induced lipid hydroperoxide formation, MCP-1
production, and monocyte transmigration. Their data suggested that apoJ reduces the
oxidative potential of LDL and artery wall cells.
The strongest connection of PON1 to the hydrolysis of lipid peroxides, cholesterol
linoleate hydroperoxides, and hydrogen peroxide comes from a study using transgenic
mice. The transgenic mice that lacked PON1 were more susceptible to atherosclerosis,
had HDLs and LDLs that were more susceptible to in vitro oxidation, and inefficient
HDL for hydrolysis of LDL in vitro (Shih et al., 1998). HDLs isolated from the
transgenic mice with PON1 had an enhanced ability to protect LDLs from oxidation
(Tward et al., 2002). The ability of PON1 and its polymorphisms to metabolize various
lipid peroxides and prevent their formation is related to susceptibility to CVD (Costa et
al., 2003).
8

Mechanism of PON1 Activity
The mechanism of PON1 protection against oxidation and atherosclerosis is still
not defined (Rozek et al., 2004). It has been suggested that the mechanism of PON1
antioxidative activity is due to the presence of detergents or unidentified proteins (Teiber
et al., 2004). Another mechanism suggests that when PON1 is released into the blood a
HDL receptor, scavenger receptor class B type 1 (SR-BI), allows the brief association of
HDL with the hepatocyte membrane without altering HDL (Thomas- Maya et al., 2006).
In the blood, PON1 function with HDL is stabilized by apoA-I and apolipoprotein J
(apoJ). Studies have also suggested that PON1’s protective mechanism against lipid
oxidation comes from having peroxidase, phospholipase A2 (PLA2), and hydrolytic
activity toward hydroperoxides and hydroxides (Teiber et al., 2004; Costa et. al., 2003).
PON1 hydrolyzes phospholipid and cholesteryl ester hydroperoxides and hydroxides
from arachidonic acid and reduces linoleic acid hydroperoxides to linoleic acid
hydroxides (Costa et al., 2003; Watson et al., 1995; Aviram et al., 1998). Other studies
have shown that copper and free radical generator 2,2’-azobis-2-amidinopropane
hydrochloride (AAPH), initiate lipid peroxidation and that possibly PON1 inhibits this
activity (Teiber et al., 2004).

PON1 Polymorphisms
The PON1 cDNA encodes a protein of 355 amino acids with a molecular mass of
43kDa, which is located on human chromosome 7q21-22 (Costa et al, 2003). The PON1
gene contains seven single nucleotide polymorphisms (SNPs), five in the promoter
sequence (G-126C, C-108T, A-162G, G-832A, G-909C) and two in the coding sequence
9

(L55M, Q192R) with linkage disequilibrium (Chen et al., 2005). Polymorphisms that
significantly affect PON1 include: L55M, Q192R, and C-108T. The L55M
polymorphism affects plasma enzymatic stability and lipid peroxidation, the Q192R
polymorphism affects the catalytic efficiency of the enzyme for various substrates, and
the C-108T polymorphism has the most significant effect on PON1 expression (Davies et
al., 1996; Chen et al., 2003). In the promoter region, the C-108T polymorphism has the
most significant effect on PON1 expression with the –108C allele resulting in PON1
levels twice that of the –108T allele (Brophy et al., 2001; Costa et al., 2005; Chen et al.,
2003). Approximately two hundred polymorphisms of PON1 have been identified, but
their function(s) have not yet been described. It has been suggested, that they are
involved in splicing efficiency and the efficiency of polyadenylation (Costa et al., 2005).
Paraoxonase activity polymorphisms result from a missense mutation in the coding
sequence of PON1. In a missense mutation, the new base alters a codon resulting in a
different amino acid being incorporated into the protein chain.

Linkage Disequilibrium
Recent work suggests the effect of polymorphism L55M on plasma enzymatic
activity is due to linkage disequilibrium with the low efficiency –108T allele of the C108T promoter region polymorphism (Chen et al., 2005). Linkage disequilibrium is the
non- random association of alleles at two or more loci. In linkage disequilibrium, some
combinations of alleles or genetic markers occur in a population more or less frequently
than expected due to random formation of haplotypes from alleles based on their
frequencies. Factors that cause linkage disequilibrium are: interactions between genes,
10

genetic linkage and the recombination rate, random drift or non- random mating, and
population structure.
Tests have shown significant linkage disequilibrium among the three promoter
polymorphisms (-909, -162, and –108) and between the promoter polymorphisms and
coding polymorphism L55M. Chen et al. (2003) used maternal blood samples (n = 402)
and umbilical cord blood samples (n = 229) to analyze linkage disequilibrium in the
Caucasian, African American, and Caribbean Hispanic population. Their results showed
that promoter polymorphisms are in almost complete linkage disequilibrium with one
another. For Caucasians, there was significant linkage disequilibrium between Q192R
and L55M and between the promoter polymorphisms and L55M. In African Americans,
the promoter polymorphisms C-108T and G-909C are in disequilibrium with Q192R, but
not in the Caucasian sample population (Chen et al., 2003). Knowledge of linkage
disequilibrium within populations may provide strategies for testing PON1
polymorphism effects in diseases, such as CVD (Jarvik et al., 2003).

PON1Q192R and CVD
The polymorphism at position 192 involves the amino acid substitution of
glutamine (Q) for arginine (R). Q192R has been shown to have significant roles in
substrate hydrolysis, drug metabolism, and susceptibility to CVD (Harel et al., 2004).
Results from previous studies have shown that PON1Q192R accounts for much variation in
PON1 hydrolysis activity of paraoxon (POase activity) and lesser variation in PON1
hydrolysis activity of diazoxon (DZOase activity) in vitro, so using diazoxon as a
substrate provides a better indication of overall PON1 activities (Jarvik et al., 2002; Costa
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et al., 2005). When measuring the substrate concentration for half maximal velocity (Km)
divided by maximal initial velocity (Vm), Li and colleagues (2000) observed that PON1
R192 allele

(Km/Vm= 6.27) is more efficient at hydrolyzing paraoxon than PON1Q192

(Km/Vm= 0.71). However, diazoxon and the nerve gases soman and sarin are
hydrolyzed more efficiently by PON1Q192 than PON1R192 (Durrington et al., 2001).
The Q192R polymorphism also affects the protective role of PON1 against
oxidative stress, where Q192 is more efficient at metabolizing oxidized HDL and LDL
than R192. Earlier data reported that approximately 30% of Caucasians are homozygous
for the R genotype, 40% are heterozygous for the QR genotype, and 30% are
homozygous for the Q genotype (Navab et al., 1997). Recent data on the distribution of
weighted PON1 allele frequencies in various populations showed that African Americans
have a weighted PON1Q192 allele frequency of 0.37 and a weighted PON1R192 allele
frequency of 0.63 (Schacchi et al., 2003). Data have shown that Caucasians have a
weighted PON1Q192 allele frequency of 0.75 (Costa et al., 2003). Allele frequencies were
determined using the gene-counting method and the genotype distribution was estimated
by the χ2 test (Schacchi et al., 2003). These data suggest that individuals carrying the
PON1R192 allele could be at increased risk for coronary artery disease when they are
exposed to environmental changes, changes in dietary habits, or contact with insecticides
and other toxic substances (Schacchi et al., 2003).
Studies on PON1 genotype suggest that genotype is an important indication of
susceptibility to cardiovascular disease. Mackness et al. (1998) found that HDL
containing the PON155MM genotype provided the most protection against LDL oxidation,
followed by PON155LM, and lastly PON155LL. They also found that of the PON1192
12

genotype PON1192QQ provided the most protection against LDL oxidation, followed by
PON1Q192R, and lastly PON1192RR. However, PON1 polymorphisms do not determine the
level of plasma PON1 activity. The variability in PON1 activity in each individual
explains why just knowing the genotype does not provide an accurate prediction of the
association of PON1 polymorphisms with disease (Costa et al., 2003).

Metabolism of PON1 Substrates
Paraoxon (diethyl 4- nitrophenyl phosphate), the active metabolite of parathion, is
formed by microsomal oxidation of parathion through desulfuration and is degraded by
hydrolysis resulting in 4-nitrophenol and diethyl phosphate via the cytochrome
P450/PON1 pathway (Neal, 1967).
Diazoxon, the active metabolite of diazinon, is formed by the microsomal
oxidation of diazinon through desulfuration and is degraded by hydrolysis resulting in
isopropyl-4-methyl-6-hydroxypyrimidine (IMHP) and diethyl phosphate via the
cytochrome P450/PON1 pathway (Shishido and Fukami, 1972).

Measuring PON1 Activity
Measuring the rate of diazoxon and paraoxon hydrolysis at high salt
concentrations (2 M NaCl), provides an accurate functional assessment of the plasma
PON1192 genotype, as well as the plasma PON1 activity for individuals (Costa et al.,
2003; Costa et al., 2005). Knowledge of genotype and phenotype is important for
determining the relationship of PON1 polymorphisms with susceptibilities to disease, the
tolerance of organophosphate insecticides, and pharmacokinetic status of drug
13

metabolism (Richter et al., 1999). A plot of the rates of diazoxon hydrolysis vs. paraoxon
hydrolysis (DZOase/POase ratio), can be used to separate individuals into three groups,
which corresponds to: PON1192QQ, PON1192QR, and PON1192RR.

Factors that Influence PON1 Activity
Many factors have been reported to affect serum PON1 activity. Simvastatin, a
drug used to reduce the amount of cholesterol and fatty substances in the blood, has been
reported to increase PON1 activity (Deakin et al., 2003). Fibrates, fibric acid derivatives
that are used to lower blood triglyceride levels, have been reported to increase PON1
activity (Gouedard et al., 2003). Aspirin has also been reported to increase PON1
activity (Blater-Garin et al., 2003). Dietary polyphenols have been reported to increase
PON1 expression by an aryl hydrocarbon- receptor dependent mechanism (Gouedard et
al., 2004). Increased dietary intake of Vitamins C and E has been reported to increase
PON1 activity by scavenging free- oxygen radical products that inhibit PON1 activity
(Jarvik et al., 2002). Other studies have not confirmed these results (Ferre et al., 2003;
Kleemola et al., 2002). Also, light alcohol consumption has been shown to increase
PON1 activity, while heavy alcohol consumption decreases PON1 activity (Rao et al.,
2003).
Smoking has been reported to decrease PON1 activity due to the presence of
reactive aldehydes and aromatic hydrocarbons in cigarettes (Nishio and Watanabe, 1997;
James et al., 2000; Jarvik et al., 2002; Senti et al., 2003; Ferre et al., 2003; Costa et al.,
2005). Heavy alcohol consumption (Costa et. al., 2005), diabetes mellitus (Boemi et al.,
2001), fat- enriched diets (Costa et al., 2005), various HDL deficiencies (Costa et al.,
14

2003; Mackness et al., 1987), and liver cirrhosis (Costa et al., 2003; Ferre et al., 2001) all
have been reported to lower PON1 activity. Studies have confirmed that low serum
PON1 activity is a predictor of vascular disease (Jarvik et al., 2000; Mackness et al.,
2001; Jarvik et al., 2003).

PON1 and Age, Gender, and Race
Some data have been reported concerning the effect of age, gender, and race on
PON1 activity. Studies have shown that serum PON1 activity is lower during
development and birth, but increases over time (Chen et al., 2003). Other studies have
reported that PON1 activities remain constant within adults or decrease in elderly
subjects (Jarvik et al., 2002; Miochevitch and Khalil, 2001; Seres et al., 2004; Costa et
al., 2005). In relation to gender, there have been conflicting studies. One study reported
a higher mean value of PON1 activity in females than males (Mueller et al., 1983). Data
presented on race and PON1, indicate that Caucasians have the more protective genotype
than African Americans (Schacchi et al., 2003; Costa et al., 2003).
Because of the limited nature of the existing data regarding the PON1
polymorphism distributions in African Americans, and the lack of this type of
information on Southern populations, this study was designed to investigate age, gender,
and race differences that are associated with PON1 in Caucasians and African Americans
from the South.
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CHAPTER II
MATERIALS AND METHODS

Substrates and Materials
Measuring the rate of diazoxon and paraoxon hydrolysis at high salt
concentrations (2 M NaCl) provides an accurate functional assessment of PON1192
genotypes, as well as the PON1 activities of individuals (Costa et al., 2003; Costa et al.,
2005). The diazoxon used in this study was obtained from Chem Service (West Chester,
PA). Paraoxon was synthesized and provided by Dr. Howard Chambers (Department of
Entomology and Plant Pathology, Mississippi State University).
The serum used in this study was obtained from blood banks in Alabama and
Tennessee through Integrated Laboratory Services-Biotech (ILSbio, LLC) in
Chestertown, Maryland. A total of two hundred serum samples were obtained from men
and women, equally distributed race and gender classes, who were self-identified as
being Caucasian or of African American origin. The following individuals were
excluded from the study: subjects under the age of twenty- five or over sixty-five,
subjects known or suspected to be infected with human immunodeficiency virus or
hepatitis, and subjects who were not Caucasian or African-American. The cardiovascular
health status, dietary and lifestyle habits, and environmental toxicant exposure of subjects
are unknown.

16

Paraoxon Hydrolysis
The discontinuous Paraoxonase assay monitors the calcium-dependent hydrolysis
of paraoxon. In the presence of salt, paraoxon hydrolysis by PON1 is activated and the
release of 4-nitrophenol is yellow in alkaline solution. The 4-nitrophenol released by
paraoxon hydrolysis was measured spectrophotometrically according to a method
described by Richter and Furlong (1999).

Paraoxonase Assay
Paraoxon, the traditional PON substrate (1.2 mM final concentration; stock
solution in dry ethanol), was incubated in paired serum samples. A calcium containing
buffer solution of Tris-HCl (0.1 M, pH 8.0), 2 mM CaCl2, and 2 M NaCl was prepared to
activate PON1 activity. An EDTA containing buffer solution of Tris-HCl (0.1 M, pH
8.0), 1 mM EDTA, and 2 M NaCl was prepared to eliminate PON1 activity. 175 μL of
calcium buffer was added to each of six wells of a microtiter plate (96 well format) and
175 μL of EDTA buffer was added to each of three wells of a microtiter plate. Six
dilutions of serum were then prepared: three calcium dilutions (60 μL calcium buffer and
15 μL of serum) and three EDTA dilutions (40 μL of EDTA buffer and 10 μL of serum).
Using a positive displacement pipette, 25 μL of the calcium dilution was added to the six
wells of the microtiter plate already containing 175 μL of calcium buffer and 25 μL of the
EDTA dilution was added to each of three wells of the microtiter plate containing 175 μL
of EDTA buffer. The solution in the microtiter plate was mixed and incubated at 37°C
for five minutes in the Jitterbug® microtiter plate shaker. Following the incubation time,
2 μL of paraoxon (1.2 mM final concentration) was added to the solution in each well of
17

the microtiter plate. The solution in the microtiter plate was mixed and incubated at 37°C
for twenty minutes in the Jitterbug® microtiter plate shaker. Following the incubation
time, the enzyme reactions were terminated by the addition of a solution of 50 μL of 20
mM EDTA and 2% Tris base solution in distilled water. The 4- nitrophenol released by
paraoxon hydrolysis was quantified spectrophotometrically at 405 nm using a TECAN
microplate spectrophotometer.

Calculation of Units/Liter
The factor for determining μmol 4-nitrophenol produced per minute per liter
serum (U/L) came from Richter and Furlong (1999), but not numbers used in the
equation:
(73.963 nmol/mL ) (106 μL/L)
AU
(20 min) (25 μL serum/mL) (103 nmol/μmol)

(3-1)

= 147.93 (U/L)/ ∆ AU
where:
73.963

=

1/Eµm

20 min.

=

25

=

μL of serum per mL

103

=

conversion factor

106

= conversion factor

reaction time

The change in absorbance units (Δ AU) was calculated from the difference between Ca++
and EDTA containing samples:
∆ AU

= (AVG. Ca++ ABS) - (AVG. EDTA ABS)
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(3-2)

The paraoxonase activity (U/L) was then calculated:
Activity

= ∆ AU
x 147.93
0.8333 cm

(3-3)

where:
0.8333 cm

=

pathlength in microplate spectrophotometer

Diazoxon Hydrolysis
To distinguish between the Q192 and R192, Richter and Furlong (1999) used an
additional substrate, diazoxon that is also well hydrolyzed by PON1. The continuous
diazoxonase assay monitors the calcium dependent production of 2-isopropyl-4-methyl6-hydroxypyrimidine (IMHP). In the presence of salt, diazoxon hydrolysis by PON1 is
activated. The IMHP released was measured spectrophotometrically according to a
method described by Richter and Furlong (1999).

Diazoxonase Assay
Diazoxon (2.0 mM final concentration; stock solution in dry ethanol) was
incubated in a single sample. A calcium buffer solution of Tris-HCl (0.1 M, pH 8.0), 2
mM CaCl2, and 2 M NaCl was prepared to activate diazoxonase activity. 20 μL of stored
human serum was pipetted into four test tubes each containing 1950 μL of calcium
buffer. The samples were warmed in a 37°C shaker bath for approximately 5 minutes.
Following the five-minute incubation time, 20 μL of diazoxon (2.0 mM final
concentration) was added to the calcium buffer and serum solution in each test tube. The
solution was vortexed and immediately placed into a 1.5 mL ultra-violet (UV) cuvette.
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The IMHP released by diazoxon hydrolysis was quantified continuously using a
conventional spectrophotometer for two minutes at 270 nm.

Calculation of Units/Liter:
The factor for determining μmol IMHP hydrolyzed per minute per liter serum
(U/L) came from Richter and Furlong (1999):
(330 nmol/mL ) (106 μL/L)
AU

(3-4)

(2 min) (10 μL serum/mL) (103 nmol/μmol)
= 16,500 (U/L)/ ∆ AU
where:
330

=

1/Eµm

2 min.

=

reaction time

10

=

μL of serum per mL

103

=

conversion factor

106

=

conversion factor

The change in absorbance units (Δ AU) were calculated from the difference between final
absorbance unit (124 seconds) and initial absorbance unit (4 seconds):
∆ AU =

(ABS 124 sec. – ABS 4 sec.)

(3-5)

The diazoxonase activity (U/L) was then calculated:
Activity

=

Δ AU x 16,500
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(3-6)

Calculation of DZOase/POase Ratio
According to Richter and Furlong (1999), plotting diazoxon hydrolysis vs.
paraoxon hydrolysis (DZOase/POase ratio), separates individuals into three genotypes of
PON1 activity: QQ, QR, and RR. This ratio can be determined by dividing diazoxonase
activity by paraoxonase activity:
Ratio

=

DZOase Activity
POase Activity

(3-7)

Statistical Analysis
The results obtained from this study were statistically analyzed using Sigma Plot
8.0, Microsoft Excel, and SAS® System for Windows, Version 9.1.
All calculations performed using the SAS® System for Windows, Version 9.1, was at the
0.05 level of significance. We used the Kolmogorov –Smirnov method to test if variables
were normally distributed. To check differences in PON1192 activities (diazoxonase and
paraoxonase) and variables (race, gender, and age) the General Linear Model (GLM)
with least square means (LSMEANS) procedure was performed. A Wilcoxon rank sum
test was also used for comparison. To check the proportion of the genotype (QQ), we
used the Binomial distribution test. Chi-Square analysis (Fisher’s exact test) was used to
test race and gender interactions (p <0.05).
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CHAPTER IV
RESULTS

Distribution of DZOase/POase Ratios and Genotype
The DZOase/POase ratio and the population distribution of PON1192 genotypes
can be determined by plotting diazoxon hydrolysis (y- axis) vs. paraoxon hydrolysis (xaxis). The diazoxonase rates vs. paraoxonase rates in the serum of African American and
Caucasian Southerners (n = 200) can be seen in Figure 1 and Table 1. Similar to previous
studies by Richter and Furlong (1999), plotting hydrolytic rates separated individuals into
one of three PON1192 phenotypes for determining PON1 status. PON1192QQ individuals
possess higher diazoxonase activities than PON1192QR and PON1192RR individuals. In
contrast, PON1192QR and PON1192RR individuals possess higher paraoxonase activities
than PON192QQ individuals. The distribution of data points for individuals possessing the
QQ genotype are visibly separated from individuals possessing QR and RR genotypes;
however, individuals possessing QR and RR genotypes are not clearly delineated.
Diazoxonase and paraoxonase assays were repeated for fifteen data points to exclude
human error. Nine data points (.045) were still indeterminate for QR and RR genotypes
by plotting diazoxonase and paraoxonase activities and analyzing mean DZOase/POase
ratios (Figure 2).
The frequency distribution of QQ (.375), QR (.325), and RR (.255) excluding
indeterminate genotypic data points can be seen in Figure 3. Chi-square analysis
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(Fisher’s exact test) was used to determine if gender relates to race in QQ, QR, and RR
genotype (including and excluding indeterminate data points). Results indicate that
gender does not relate to race including and excluding the indeterminate data points
within the QQ and QR genotypes. However, results do indicate that gender does relate to
race including (p = 0.0495) and excluding (p = 0.0344) indeterminate data points within
the RR genotype. Race and gender interactions were not expected and may be attributed
to the samples obtained in this study.

Observed Differences in African Americans and Caucasians
Results from the General Linear Model (GLM) with least squares means
(LSMEANS) procedure indicate significant race (p = 6.39-14) differences in mean
DZOase/POase ratios of African Americans and Caucasians (Figure 4). Results from the
Wilcoxon rank sum test also indicate differences at p<0.0001.
PON1192 genotype distribution and mean DZOase/POase ratios were determined
for African American Southerners (n = 100). Plotted diazoxonase activities vs.
paraoxonase activities in the serum of African American Southerners can be seen in
Figure 5a. The frequency distribution of QQ (.15), QR (.34), and RR (.44) genotypes
within the African American population were determined. The mean DZOase/POase
ratio of African American females (31.19 ± 25.96) and males (25.87 ± 21.49) is shown in
Table 2. The lower ratio indicates that the R allele is more prevalent in the sample
population than the Q allele. For seven data points of African Americans (3 females; 4
males), the genotype (QR or RR) could not be determined. PON1192 genotype
distribution and mean DZOase/POase ratios were also determined for Caucasian
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Southerners (n = 100). The frequency distribution of QQ (.60), QR (.31), and RR (.07)
genotypes can be seen in Figure 5b. The mean DZOase/POase ratio of Caucasian
females (65.36 ± 28.43) and males (54.18 ± 31.62) was also calculated (Table 2). The
higher frequency distribution of QQ and their significantly higher mean DZOase/POase
ratios than African Americans indicates that that the Q allele is more prevalent than the R
allele. For two data points of Caucasians (1 female; 1male), the genotype (QR or RR)
could not be determined.
A 95% confidence interval was calculated for the proportion (P) of the QQ data
for African Americans (.15) and Caucasians (.60):
95% CI = P ± 1.96 √ P (1-P)
√n

(4-1)

The 95% CI for Caucasians (.60 ± .15) and African Americans (.15 ± .11) indicate a
significant difference in the QQ genotype between the two populations. Results from the
binomial distribution test also indicate a significant difference in the proportion of
African Americans and Caucasians with the QQ genotype (p < .0001). Statistical
analyses of PON1192 genotype distribution and mean DZOase/POase ratios in the serum
of African American and Caucasian Southerners indicate a positive correlation between
PON1192 genotype and mean DZOase/POase ratios.

Differences in Race and PON1192
Differences in DZOase/POase ratios were further analyzed by calculating
diazoxonase and paraoxonase activities independently to examine possible differences
between the races. The mean diazoxonase activities of African Americans (5972.73 ±
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2064.62) and Caucasians (7720.30 ± 2226.64) were compared (Table 3). Results from
the GLM with LSMEANS procedure show that Caucasians exhibit significantly higher
diazoxonase activities than African Americans, p = 3.25-08 (Figure 6).
The mean paraoxonase activities of African Americans (297.36 ± 143.93) and
Caucasians (183.36 ± 120.81) were also analyzed (Table 3). Results from the GLM with
LSMEANS procedure show that African Americans exhibit higher paraoxonase activities
than Caucasians, p = 6.52-09 (Figure 7). The significant differences in diazoxonase
activities and paraoxonase activities between the races suggest a positive association
between PON1 activities and race.

Differences in Gender and PON1192
Results from the GLM with LSMEANS procedure indicate no significant gender
differences when comparing diazoxonase (Figure 8a) and paraoxonase (Figure 9a)
activities. There were also no significant gender differences in diazoxonase activities
within race (Figure 8b) or gender differences in paraoxonase activities within race
(Figure 9b).
Statistical analysis did indicate a significant difference in DZOase/POase ratios
when comparing females and males, p = .0328 (Figure 10). These results indicate that
females (48.27 ± 32.07) have higher DZOase/POase ratios than males (40.03 ± 30.43).
Differences in genotype distribution among females and males were not expected and
may be attributed to the samples obtained in this study or to some as yet unidentified sex
linkage.
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Differences in Age and PON1192
Conflicting results on age and PON1 activity led us to analyze age as a function
that possibly affects PON1 enzymatic activities. Individuals were separated into three
age groups: 20-30 years, 30-40 years, and 40+ years for statistical analysis. Results from
the GLM with LSMEANS procedure showed a statistically significant difference in
paraoxonase activities (p = .0366) and DZOase/POase ratios (p = .0062) between the
youngest (n = 32) and oldest (n = 32) age groups in females (Figures 12 and 13).
The findings suggest differential changes may occur in PON1192 activities with
age. Results show that the youngest females have higher paraoxonase activities (278.23
± 147.22) than the oldest females (179.92 ± 135.99). The opposite is true for
diazoxonase activities in the youngest females (6527.68 ± 2226.01) compared to the
oldest females (7503.27 ± 2577.52). This analysis indicates that with age, changes in
paraoxonase activities may render a higher DZOase/POase ratio in females.
Results from the GLM with LSMEANS procedure also showed a statistical
significant difference in paraoxonase activities (p = .0209) and a marginally significant
difference in DZOase/POase ratios (p = .0543) between the youngest (n = 28) and the
oldest (n = 45) age groups in males (Figures 15 and 16).
A different trend was found when comparing PON1192 activities in males. Results
showed that the oldest males (284.68 ± 138.64) have higher paraoxonase activities than
the youngest males (210.48 ± 122.25). The opposite is true for diazoxonase activities in
the youngest males (7064.31 ± 2263.73) compared to the oldest males (6519.52 ±
2222.66). This analysis indicates that with age, changes in paraoxonase activities may
render a lower DZOase/POase ratio in males.
26

However, results did not show significant differences when analyzing the middle
age group or differences in diazoxonase activities among the three age groups in females
and males (Figures 11 and 14). Differences found in mean DZOase/POase ratios of both
genders may also be due to the samples obtained.
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Figure 1. DZOase vs. POase Activities in the Serum of African
American and Caucasian Southerners
Abbreviations are as follows: AAF, African American female (●); AAM, African
American male (■); CF, Caucasian female (○); CM, Caucasian male (□). Sample
population (n = 200) consisted of 50 AAF, 50 AAM, 50 CF, and 50 CM. The
distribution of individuals into three PON1192 genotypes (QQ, QR, and RR) is also
shown.
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Figure 2. DZOase vs. POase Activities in the Serum of African
American and Caucasian Southerners with Indeterminate
Data Points for QR and RR
Distribution of data points for nine individuals where QR and RR genotypes
were indeterminate using diazoxonase and paraoxonase activities and mean
DZOase/POase ratios. Abbreviations and symbols are identical as in Figure 1.
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Figure 3. DZOase vs. POase Activities in the Serum of African
American and Caucasian Southerners Excluding
Indeterminate Data Points
Frequency distribution of QQ, QR, and RR in 47 AAF, 46 AAM, 49 CF, and 49
CM. Indeterminate data points were excluded (3 AAF; 4AAM; 1 CF; and 1 CM).
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Figure 4. Mean DZOase/POase Ratios in the Serum of African
American and Caucasian Southerners
Values are expressed as mean ± SD (n = 100) within each race. Significant
differences were determined using the GLM with LSMEANS procedure (p<0.05). P
–value represents significant difference found when comparing race.
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Figure 5a. DZOase vs. POase Activities in the Serum of African American
Southerners
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Figure 5b. DZOase vs. POase Activities in the Serum of Caucasian Southerners
Abbreviations and symbols are identical as in Figure 1. The frequency
distribution QQ, QR, and RR can be determined. Indeterminate data points for QR
and RR genotypes in African Americans (7) and Caucasians (2) can be seen in Figure
2.
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Figure 6. Mean DZOase Activities in the Serum of
African American and Caucasian Southerners
Values are expressed as mean ± SD (n = 100) within each race. Significant
differences were determined using the GLM with LSMEANS procedure (p<0.05). P
–value represents significant difference found when comparing race.
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Figure 7. Mean POase Activities in the Serum of
African American and Caucasian Southerners
Abbreviations are identical as in Figure 1. Values are expressed as mean ± SD
(n = 200). Significant differences were determined using the GLM with LSMEANS
procedure (p<0.05). P–value represents significant difference found when comparing
race.
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Figure 8a. Mean DZOase Activities in the Serum of Females and Males
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Figure 8b. Mean DZOase Activities in the Serum of African American
and Caucasian Southerners
Abbreviations are identical as in Figure 1. (a) Values are expressed as mean ±
SD (n = 100) within each gender. (b) Values are expressed as mean ± SD (n = 50)
within each gender and race. Significant differences were determined using the GLM
with LSMEANS procedure (p<0.05). Contrasting letters (a* & b* -females; a & b males) represent significant differences found comparing race. No differences within
groups having similar letters.
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Figure 9a. Mean POase Activities in the Serum of Females and Males
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Figure 9b. Mean POase Activities in the Serum of African American
and Caucasian Southerners
Abbreviations are identical as in Figure 1. (a) Values are expressed as mean ±
SD (n = 100) within each gender. (b) Values are expressed as mean ± SD (n = 50)
within each gender and race. Significant differences were determined using the GLM
with LSMEANS procedure (p<0.05). Contrasting letters (a* & b* -females; a & b males) represent significant differences found comparing race. No differences within
groups having similar letters.
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Figure 10. Mean DZOase/POase Ratios in the Serum of Females
and Males
Values are expressed as mean ± SD (n = 100) within each gender. Significant
differences were determined using the GLM with LSMEANS procedure (p<0.05). P
–value represents significant difference found when comparing race.
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Figure 11. Mean DZOase Activities in the Serum of Three Age Groups
African American and Caucasian Female Southerners
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Figure 12. Mean POase Activities in the Serum of Three Age Groups
African American and Caucasian Female Southerners

Above figures, values are expressed as mean ± SD (n = 100): females 25-30 (n =
32), 30-40 (n = 36) and above 40 (n = 32). Significant differences were determined
using the binomial distribution test, p < 0.05. For paraoxonase, p- value represents
the significant difference found among 25-30 (n = 32) and above 40 females.
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Figure 13. Mean DZOase/POase Ratios in the Serum of Three Age
Groups of African American and Caucasian Female
Southerners
Values are expressed as mean ± SD (n = 96). Significant differences were
determined using the binomial distribution test, p < 0.05. P- value represents the
significant difference found among 25-30 (n = 30) and above 40 (n = 30) females.
Ratios of indeterminate data points were not included.
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Figure 14. Mean DZOase Activities in the Serum of Three Age Groups
of African American and Caucasian Male Southerners
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Figure 15. Mean POase Activities in the Serum of Three Age Groups
of African American and Caucasian Male Southerners
Above figures, values are expressed as mean ± SD (n = 100); males 25-30 (n =
28), 30-40 (n = 25) and above 40 (n = 47). Significant differences were determined
using the binomial distribution test, p < 0.05. For paraoxonase, p- value represents
the significant difference found among 25-30 (n = 28) and above 40 (n = 47) males.
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Figure 16. Mean DZOase/POase Ratios in the Serum of Three
Age Groups of African American and Caucasian Male
Southerners
Values are expressed as mean ± SD (n = 99). Significant differences were
determined using the binomial distribution test, p < 0.05. P- value represents the
significant difference found among 25-30 (n = 27) and above 40
(n = 45) males.
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Table 1. PON1192 Genotype Distribution in the Serum of African American and
Caucasian Southerners
POase (Units/Liter)

DZOase (Units/Liter)

Mean ± SD
240 ± 144

Range

Mean ± SD

All

Range
29 - 614

2140 -14083

6847 ± 2314

QQ

29 - 170

98 ± 34

2417 - 14083

7950 ± 2446

.375

QR

115 - 445

265 ± 80

3622 - 10312

7132 ± 1825

.325

RR

206 - 614

408 ± 104

2140 - 10131

5210 ± 1595

.255

n = 200

Frequency

Data from Sigma Plot 8.0 (Figure 1).
Table 2. Mean PON1192 Activities and DZOase/POase Ratios in the Serum of African
American and Caucasian Southerners by Gender
Race and Gender
AA- female a
AA- male

a

C- female
C- male

b

b

Paraoxonase Activity

Diazoxonase Activity

DZOase/POase ratios

300.10 ± 161.95

6288.85 ± 2193.03

31.19 ± 25.96

294.61 ± 124.95

5656.61 ± 1897.09

25.87 ± 21.49

160.63 ± 108.73

7849.22 ± 2334.96

65.36 ± 28.43

206.08 ± 128.88

7591.38 ± 2128.62

54.18 ± 31.62

Values are represented as mean ± SD of fifty individuals of each race and gender.
a,b

Significant differences in activities and DZOase/POase ratios

Table 3. Mean PON1192 Activities and DZOase/POase Ratios in the Serum of African
American and Caucasian Southerners
Race
African Americans
Caucasians

Paraoxonase Activity

Diazoxonase Activity

DZOase/POase ratios

a

297.36 ± 143.93

5972.73 ± 2064.62

28.53 ± 23.86

183.36 ± 120.81

a

59.77 ± 30.44a

7720.30 ± 2226.64

Values are represented as mean ± SD of two hundred individuals.
a

Significant differences in activities and DZOase/POase ratios (p <0.05).
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CHAPTER V
DISCUSSION

PON1 plays an important role in hydrolyzing many substrates, including oxidized
lipoproteins and active metabolites of organophosphate insecticides. The single
nucleotide polymorphism at position 192 has a significant effect on PON1 hydrolytic
activity, drug metabolism, and the onset of cardiovascular disease (Harel et al., 2004).
Regarding the PON1Q192R polymorphism, the Q allele has been shown to be more
efficient in metabolizing diazoxon and to have the more protective function in decreased
susceptibility to cardiovascular disease. In contrast, the R allele has been shown to be
more efficient in metabolizing paraoxon and less protective in preventing the onset of
cardiovascular disease (CVD). Statistical analysis has indicated that CVD is more
prevalent in the African American population and causes higher annual age-adjusted
mortality rates in the South (excluding Florida) than any other region in the United
States. Many environmental, dietary, lifestyle, and genetic factors have been reported to
be associated with the onset of CVD; however, data on the distribution of PONQ192R in
the serum of Southerners and African Americans in the South remain unknown.
This study has determined the PON1192 genotype distribution, PON1192 enzymatic
activities (paraoxonase and diazoxonase), and mean DZOase/POase ratios in the serum of
two hundred African American and Caucasian Southerners. This examination also
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revealed a significant association of PON1192 activities with race, gender, and age. The
PON1192 genotype frequency distribution in the Southern population: QQ (.375), QR
(.325), and RR (.255) excluding indeterminate (QR and RR) data points (.045) indicate
that more data points from the population fall into the protective genotype. Results from
this study show that Caucasians (60%) have an overwhelmingly higher distribution of the
QQ genotype than African Americans (15%). Our study supports data reported by Costa
(2003) and Schacchi (2003) on Q and R allele frequencies in African Americans and
Caucasians. African Americans were reported to have a higher R allele frequency (0.63)
and Caucasians were reported to have a higher Q allele frequency (0.75). Data strongly
suggest that more African Americans in the South have the genotypes associated with
increased susceptibility to CVD than Caucasians.
Differences seen among Caucasians and African Americans suggest that linkage
disequilibrium may play a critical role in determining the distribution of PON1192
genotypes. According to a study by Chen et al. (2003), in Caucasians there is linkage
disequilibrium between polymorphisms Q192R and L55M and between the promoter
polymorphisms and L55M. In African Americans, the promoter polymorphisms C-108T
and G-909C are in disequilibrium with Q192R, but not in the Caucasian sample
population. Factors that cause linkage disequilibrium are: interactions between genes,
genetic linkage and the recombination rate, random drift or non- random mating, and
population structure. The risk of CVD may be synergized with the less protective
genotype and factors such as poor lifestyle habits (high alcohol consumption, smoking),
fat- enriched dietary intake, and environmental toxicant exposure (insecticides). It would
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be of interest to also study lifestyle, dietary, and environmental factors that affect
PON1192 activities.
The mean DZOase/POase ratios were significantly different when comparing
African Americans to Caucasians using the GLM with LSMEANS procedure. The mean
DZOase/POase ratios are indicative of the PON1192 genotype distribution within each
population. The higher mean DZOase/POase ratio of Caucasians compared to African
Americans suggests a higher frequency of the more protective PON1192 genotype (QQ)
and higher diazoxonase activities within the Caucasian population. It has recently been
revealed in a Serbian study that HDL and LDL particle size are associated with
diazoxonase activity (Vekic et al., 2007). Small and dense LDL particles (sdLDL)
undergo oxidation readily and the large size of HDL has been associated with
hydrolyzing sdLDL particles. Results from this study found that sdLDL particles
increase oxidative stress, which stimulates PON1 diazoxonase activity. The increased
oxidative stress causes an accumulation of smaller, denser HDL particles decreasing
HDL antioxidative activity (Vekic et al., 2007).
Examining the PON1192 genotype distribution and mean DZOase/POase ratios,
we hypothesized higher diazoxonase activities in Caucasians and higher paraoxonase
activities in African Americans. Our results show significant differences in diazoxonase
and paraoxonase activities between African American and Caucasian Southerners
independently. Caucasians demonstrated higher mean diazoxonase activities than
African Americans; in contrast, African Americans demonstrated higher mean
paraoxonase activities than Caucasians. The higher paraoxonase activity in African
Americans denotes the dominant presence of the R allele. The higher diazoxonase
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activity in Caucasians denotes the dominant presence of the Q allele. Our study indicates
a positive correspondence between PON1192 activities and race.
Gender differences in PON1 activities have not been shown to be significant in
many studies (Mueller et al., 1983). Results from our study do not indicate a significant
difference when comparing diazoxonase and paraoxonase activities of females and males
separately or within each race. Our results did indicate a significant difference when
comparing DZOase/POase ratios of females and males. Differences in the higher mean
DZOase/POase ratios of females than males may be attributed to one or two factors, the
samples obtained in this study or to some as yet unidentified sex linkage. Our serum
samples were randomly obtained from individuals in Alabama and Tennessee blood
banks, so more females with QQ genotype may have been selected than males with the
QQ genotype. If non- random sampling was not involved, our data suggest that
regardless of PON1192 activities, females are more likely to be born with the more
protective genotype than males. Further studies are needed to determine if direct
correlation between gender and PON1192 DZOase/POase ratios exists.
Our study reports that with age, paraoxonase activity decreases in females and
DZOase/POase ratios shift to become higher. In males, we found that paraoxonase
activity increases with age and DZOase/POase ratios shift to become lower. These
results indicate that with age, changes in paraoxonase activities may render a lower
DZOase/POase ratio in the oldest males, but higher DZOase/POase ratios in the oldest
females. A higher DZOase/POase ratio is indicative of having the more protective
PON1192 genotype associated with decreased susceptibility to CVD. A lower
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DZOase/POase ratio is indicative of having the less protective PON1192 genotype
associated with increased susceptibility to CVD.
Studies have shown that serum PON1 activity is lower during development and
birth, but increases over time (Chen et al., 2003). Other studies have reported that PON1
activities remain constant within adults or decrease in elderly subjects (Jarvik et al., 2002;
Miochevitch and Khalil, 2001; Seres et al., 2004; Costa et al., 2005). From the data
presented here, and previous studies, it is clear that further studies are needed to
determine the relationship between PON1192 and age.
In summary, our results report the PON1192 genotype distribution, PON1192
enzymatic activities (paraoxonase and diazoxonase), and mean DZOase/POase ratios in
the serum of African American and Caucasian Southerners. Most importantly, our study
reports significant race, gender, and age differences associated with PON1192 activities. A
higher frequency of African Americans possess the less protective genotype and a higher
frequency of Caucasians possess the more protective genotype linked with CVD. This is
due to the higher paraoxonase activities of African American Southerners and higher
diazoxonase activities of Caucasian Southerners.
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